Israeli biotech firm signs $320 million deal to sell drug in US, Canada | The Jerusalem Post

D-PLEX100 is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent abdominal surgical site infections.

Raccontata dajpost.com